The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 72 (high attention) · dilution pressure elevated · listing risk low · governance risk low · runway 0.8 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (shelf filed). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 25 |
| Jul 20, 2026 | ▼ Shelf filed | S-1/A filed 2026-07-20 filing | 32 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.8 months runway: liquidity $64,829 (cash $45,480 + investments $19,349) as of 2026-06-30, burn $1,024,206/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 49 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $5,352,889 (as of 2025-12-31) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 26 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $64,829 vs current liabilities $2,939,317 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →